Article

COA and ASCO Issue Joint Statement on Oncology Payment Reform

COA and ASCO are issuing a joint statement on payment reform in cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

COA and ASCO are issuing a joint statement on payment reform in cancer care. The statement results from collaboration between the two organizations, in concert with AmerisourceBergen/ION and McKesson/US Oncology, to arrive at principles to guide the evolution of health care payment systems that support high-quality, high-value cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

Read the full story here: http://bit.ly/1eexzCn

Source: Community Oncology Alliance

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Matias Sanchez, MD
Screenshot of an interview with Nadine Barrett, PhD
dr carol regueiro
dr carol regueiro
dr carol regueiro
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
Related Content
Highlights From ASCO 2024
December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor
Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Top 5 AJMC journal articles of 2024
December 19th 2024

Top 5 Most-Read AJMC® Journal Articles of 2024

Christina Mattina
In 2024, the most-read articles published in our flagship peer-reviewed journal, The American Journal of Managed Care® (AJMC®), touched on disease burden, policy consequences, and more.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Clif Gaus, ScD, MHA | Image Credit: © NAACOS
December 16th 2024

Smart, Effective Advocacy: Clif Gaus’ Vision for Value-Based Care

Maggie L. Shaw
Since its founding in 2012, the National Association of ACOs has evolved from a group of 30 to 477 accountable care organization members covering 9.2 million beneficiary lives.
FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
December 16th 2024

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Kristi Rosa
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo